Submit to the TCT 2019 calls for science for the opportunity to share your work with colleagues and experts from across the globe. Please see submission details and deadlines below.
Questions? Please email firstname.lastname@example.org
Late-Breaking Clinical Trials are typically first-time international or US presentations of the primary endpoint or important secondary endpoint results of prospective, randomized clinical trials or of large-scale, impactful single-center or multicenter registries.
Late-Breaking Clinical Science submissions are the first worldwide presentations of smaller randomized trials, impactful single-center or multicenter registries, or first-in-man experiences with novel devices or drugs. Accepted submissions will be presented in the Main Arena at TCT 2019, and during press conferences scheduled on the same days as the Main Arena presentations.
The following rarely qualify as Late-Breaking Clinical Trial submissions: preclinical studies, early first-in-human device studies, and meta-analyses; these should be submitted as Abstracts or as Interventional Innovations.
TCT is always looking to present fascinating and futuristic concepts and ideas that relate to improving outcomes for patients with cardiovascular disease.
Submit your ideas for an interesting lecture you would like to present that is not typical for large CV congresses.
Examples might include: digital health, machine learning, artificial intelligence, micro-imaging breakthroughs, regionalized systems of care, nano-technologies, regulatory reform, role of social media, fetal therapies for prevention, etc. Anything novel will be considered!
Abstract submissions should address an area of interventional cardiology, endovascular medicine, or structural heart disease and constitute original research, but may include portions of prior abstracts and/or manuscripts presented elsewhere. Clinical studies, basic science investigation, and preclinical studies are equally encouraged. Reports of a single patient should be submitted to Challenging Cases, regardless of the novelty of the individual case.
Physicians from around the world are invited to submit their most challenging coronary, endovascular, and structural heart disease cases. The directors of TCT review each submitted case and select the best for presentation.
TCT is the preeminent platform for the initial presentation of novel technological concepts in the field of interventional vascular therapy.
We are actively soliciting for emerging innovative concepts to be presented at TCT 2019. Participants are invited to submit their novel technologies relevant to the monitoring, diagnosis, and treatment of coronary, endovascular, or structural heart disease. Selected emerging technologies will be presented at TCT 2019.
Submitters are also encouraged to participate in the Shark Tank Innovation Competition. All technologies submitted to the Innovation Competition must: a) address an unmet clinical need, b) have preliminary patent application filed, and c) include pre-clinical or early human clinical data.
Join TCT Associate Director Ori Ben-Yehuda, MD and our TCT International Council Fellows Committee for the TCT International Fellows Session. International fellows are encouraged to submit their challenging cases. The top three challenging cases will be presented by the winners. Then watch fellows from around the world present their challenging cases in a section we call “Fellows Got Talent!” Vote for your favorite! Finally learn from the experts on the International Council as they present their favorite challenging cases.
Criteria for International Fellows: Age limit: Less than 38 years of age. Postgraduate degree MD, FCPS, FCCP, or DM Enrollment in cardiology fellowship program
A letter of recommendation is required from the immediate supervisor or by the Institute Head, submissions without a supervisor letter will not be accepted.
Supported through an educational grant from ABIOMED, Inc.
Physicians enrolled in a fellowship program may submit a “most challenging case” demonstrating the successful use of the Impella device. Please provide a brief description of patient history, clinical diagnosis, case decisions, and patient outcome. Applicants with the top three cases will be selected for a scholarship to TCT and will present their case at a Breakfast Meeting.
Supported through an educational grant from Getinge
Physicians enrolled in a fellowship program may submit an interesting or unique clinical case of a patient who benefited from counter-pulsation therapy for one of the following indications:
Applicants with the top three case submissions will receive a scholarship to attend TCT and will present their case at a Breakfast Meeting.
This award recognizes clinical and academic excellence in interventional cardiovascular medicine and aims to stimulate the continued commitment and dedication to both outstanding patient care and ongoing academic inquiry by young investigators. The three finalists will become faculty at TCT 2019. The winner will be announced at TCT 2019, and the award and a $10,000 scholarship will be presented in the Main Arena.
Candidates for this award must be less than 40 years of age at the start of TCT 2019 (September 25, 2019), specializing in interventional cardiovascular medicine (interventional cardiology, endovascular medicine, structural heart disease, pathology, etc.). Candidates may be from any country and we encourage international, as well as US applications.